Seventy‐Two‐Week Real‐World Outcomes of Tralokinumab Treatment for Moderate‐To‐Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity

An anti-interleukin-13 antibody tralokinumab is effective for atopic dermatitis (AD). However, there are no real-world studies on its long-term outcomes in patients stratified by rash and itch severity. To evaluate the effectiveness of 72-week tralokinumab treatment in 4 groups of AD patients, stratified by baseline investigator's global assessment (IGA) and peak pruritus numerical rating scale (PP-NRS), we conducted a prospective study of 167 Japanese patients with moderate-to-severe AD from October 2023 to October 2025. Patients received tralokinumab every two weeks. Eczema area and severity index (EASI), IGA, and PP-NRS were assessed at weeks 0, 4, 12, 16, 24, 36, 48, 60, and 72. Data were analyzed separately in 4 groups; IGA 3/PP-NRS < 7, IGA 3/PP-NRS ≥ 7, IGA 4/PP-NRS < 7, and IGA 4/PP-NRS ≥ 7. Mean EASI and PP-NRS decreased in all groups through week 72. The rates achieving IGA 0/1, EASI 100, and PP-NRS ≥ 4-point reduction were highest in the group with IGA 3/PP-NRS ≥ 7 (53.6%, 17.9%, and 92.0%) while lowest in that with IGA 4/PP-NRS < 7 (10.0%, 0%, and 22.2%). Tralokinumab improved rash and itch throughout 72 weeks across all groups stratified by rash and itch severity.